title: Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
abstract: Small cell lung cancer (SCLC) is a very aggressive disease, characterised by rapid growth, high response rates to both chemotherapy and radiotherapy and subsequent development of treatment resistance in the vast majority of patients. In the past 30 years, little progress has been made in systemic treatments and the established management paradigm of platinum-based chemotherapy has reached an efficacy plateau. Several clinical trials have investigated targeted therapies, without producing clinically significant benefits. Recently presented early phase clinical trials with immune checkpoint inhibitors (blockade of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) and blockade of the programmed cell death-1 (PD-1) receptor) have shown promising results. In this review, we present the emerging evidence on immune checkpoint blockade for SCLC.
authors.affiliation: Department of Medical Oncology , Santa Maria della Misericordia Hospital , Perugia , Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Paglialunga
authors.affiliation: Department of Medical Oncology , The Christie NHS Foundation Trust , Manchester , UK.
authors.forename: Zena
authors.initials: Z
authors.lastname: Salih
authors.affiliation: Department of Medical Oncology , Santa Maria della Misericordia Hospital , Perugia , Italy.
authors.forename: Biagio
authors.initials: B
authors.lastname: Ricciuti
authors.affiliation: Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Department of Medical Oncology, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Califano
keywords: immune checkpoint; ipilimumab; nivolumab; pembrolizumab; small cell lung cancer